ADCs, Chemotherapy, and Checkpoint Blockade in Urothelial Carcinoma
Update: 2025-11-24
Description
About this podcast:
This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center.
Dr Rosenberg focuses on:
This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center.
Dr Rosenberg focuses on:
- The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancer
- The potential role of Immunogenic Cell Death and whether it has a clinical impact on patient care and creating an anti-tumor immune response
- Enfortumab vedotin, an ADC targeting Nectin-4
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
